Personalis (PSNL) to Release Quarterly Earnings on Tuesday

Personalis (NASDAQ:PSNL - Get Free Report) is expected to be releasing its Q1 2025 earnings data after the market closes on Tuesday, May 6th. Analysts expect Personalis to post earnings of ($0.23) per share and revenue of $17.41 million for the quarter. Personalis has set its FY 2025 guidance at EPS and its Q1 2025 guidance at EPS.

Personalis (NASDAQ:PSNL - Get Free Report) last issued its quarterly earnings results on Thursday, February 27th. The company reported ($0.23) EPS for the quarter, topping analysts' consensus estimates of ($0.32) by $0.09. The company had revenue of $16.80 million during the quarter, compared to analyst estimates of $15.48 million. Personalis had a negative return on equity of 66.07% and a negative net margin of 104.52%. On average, analysts expect Personalis to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Personalis Price Performance

Shares of Personalis stock traded up $0.30 during midday trading on Friday, hitting $4.16. The company had a trading volume of 131,079 shares, compared to its average volume of 974,636. Personalis has a 1-year low of $1.14 and a 1-year high of $7.20. The business's 50 day simple moving average is $3.62 and its two-hundred day simple moving average is $4.47. The stock has a market cap of $366.92 million, a PE ratio of -2.45 and a beta of 1.89.

Wall Street Analysts Forecast Growth

Several research firms have recently issued reports on PSNL. Lake Street Capital boosted their price objective on shares of Personalis from $7.00 to $9.00 and gave the stock a "buy" rating in a report on Wednesday, January 8th. HC Wainwright reaffirmed a "buy" rating and issued a $8.00 price target on shares of Personalis in a report on Friday, February 28th. Needham & Company LLC reissued a "buy" rating and set a $7.00 price objective on shares of Personalis in a report on Thursday, April 10th. Finally, Craig Hallum initiated coverage on shares of Personalis in a research note on Monday, March 17th. They set a "buy" rating and a $8.00 price target on the stock. Five analysts have rated the stock with a buy rating, According to data from MarketBeat, Personalis currently has an average rating of "Buy" and a consensus target price of $7.80.

About Personalis

Personalis, Inc develops and markets advanced cancer genomic tests and analytics primarily in the United States, Europe, and the Asia-Pacific. Its tests and analytics are used by pharmaceutical companies for translational research, biomarker discovery, and development of personalized cancer therapies, as well as advanced tests are used by physicians to detect cancer recurrence, monitor cancer evolution, and uncover insights for therapy selection.